November 2015 Newsletter

November 1, 2015:

‘Hype Cycle’ Shapes Expectations for Disruptive Technology in Ophthalmology

Most ophthalmologists and industry followers can point to products that have ridden this wave.

November 1, 2015:

Eye Hospital Construction Boom in China Continues

Xiamen University’s 1,500-bed facility is the largest project underway.

November 1, 2015:

AAO Expects Record Attendance at Meeting in Vegas

Preregistration is up 21 percent over the 2014 total for the world’s biggest ophthalmic conference.

November 1, 2015:

Countdown to the 2015 AAO Meeting: What We’re Expecting

The meeting offers ample coverage of promising retinal products, but dry eye treatments and glaucoma drugs receive little attention.

November 1, 2015:

Must-See Sessions at the 2015 AAO Meeting

November 1, 2015:

Shire Announces OPUS-3 Lifitegrast Data, Readies New FDA Filing

Third Phase III trial did not include endpoints that objectively measured improvement in signs.

November 1, 2015:

Valeant Hits Turbulence on Mission to Become Big Pharma Company

The firm faces three US government probes and was forced to cut ties with a specialty pharmacy that generated significant revenues for Valeant.

November 1, 2015:

Presbyopia Market Expands Quickly to Address Changing Vision Needs

Segment is forecast to grow to $906 million at the manufacturer level by 2020.

November 1, 2015:

Allergan and Pfizer in Merger Talks to Create $330 Billion Pharma Giant

A deal would be the largest takeover in a record-setting year for mergers and acquisitions.

November 1, 2015:

54 Class Action Lawsuits Accuse Contact Lens Makers of Price Fixing

The companies face additional legal challenges, including a Utah law prohibiting their minimum pricing policies.

November 1, 2015:

Encore Vision Enrolls First Subject in Study of Eye Drop for Presbyopia

EV06 is being developed to reverse age-related changes in the crystalline lens that result in diminished lens elasticity.

November 1, 2015:

G20 Ministers Back Plan to Close Tax Loopholes for Multinational Firms

Many recent mergers in the pharmaceutical industry have been fueled by the low tax rates and loopholes in countries such as Luxemburg, Canada, and Ireland.

November 1, 2015:

Ziemer Receives FDA Approval for FEMTO LDV Z8

The device gained Health Canada approval and CE marking earlier in the year.

November 1, 2015:

Surgeons’ Plans for EDOF IOLs: Early Q3-2015 Results

Early responses suggest that 18 percent plan to offer the lenses to all patients.

November 1, 2015:

November 2015 OMP

Social media